LIGAND PHARMACEUTICALS (LGND) Fundamental Analysis & Valuation

NASDAQ:LGND • US53220K5048

Current stock price

203.61 USD
+4.02 (+2.01%)
At close:
203.61 USD
0 (0%)
After Hours:

This LGND fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. LGND Profitability Analysis

1.1 Basic Checks

  • LGND had positive earnings in the past year.
  • In the past year LGND had a positive cash flow from operations.
  • In multiple years LGND reported negative net income over the last 5 years.
  • Each year in the past 5 years LGND had a positive operating cash flow.
LGND Yearly Net Income VS EBIT VS OCF VS FCFLGND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

1.2 Ratios

  • LGND has a Return On Assets of 7.97%. This is amongst the best in the industry. LGND outperforms 89.06% of its industry peers.
  • The Return On Equity of LGND (12.23%) is better than 86.46% of its industry peers.
  • LGND's Return On Invested Capital of 2.45% is fine compared to the rest of the industry. LGND outperforms 79.69% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for LGND is significantly below the industry average of 13.06%.
  • The 3 year average ROIC (1.82%) for LGND is below the current ROIC(2.45%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.97%
ROE 12.23%
ROIC 2.45%
ROA(3y)4.72%
ROA(5y)2.84%
ROE(3y)6.4%
ROE(5y)4.11%
ROIC(3y)1.82%
ROIC(5y)2.16%
LGND Yearly ROA, ROE, ROICLGND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

1.3 Margins

  • With an excellent Profit Margin value of 46.42%, LGND belongs to the best of the industry, outperforming 96.88% of the companies in the same industry.
  • LGND has a better Operating Margin (17.61%) than 85.94% of its industry peers.
  • In the last couple of years the Operating Margin of LGND has grown nicely.
  • LGND has a better Gross Margin (94.57%) than 95.31% of its industry peers.
  • LGND's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 17.61%
PM (TTM) 46.42%
GM 94.57%
OM growth 3Y125.81%
OM growth 5Y30.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.97%
GM growth 5Y2.47%
LGND Yearly Profit, Operating, Gross MarginsLGND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 200 300 400 500

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. LGND Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), LGND is destroying value.
  • LGND has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for LGND has been increased compared to 5 years ago.
  • Compared to 1 year ago, LGND has a worse debt to assets ratio.
LGND Yearly Shares OutstandingLGND Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
LGND Yearly Total Debt VS Total AssetsLGND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • LGND has an Altman-Z score of 5.82. This indicates that LGND is financially healthy and has little risk of bankruptcy at the moment.
  • LGND's Altman-Z score of 5.82 is fine compared to the rest of the industry. LGND outperforms 79.17% of its industry peers.
  • The Debt to FCF ratio of LGND is 9.12, which is on the high side as it means it would take LGND, 9.12 years of fcf income to pay off all of its debts.
  • LGND's Debt to FCF ratio of 9.12 is fine compared to the rest of the industry. LGND outperforms 79.17% of its industry peers.
  • LGND has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
  • LGND's Debt to Equity ratio of 0.44 is on the low side compared to the rest of the industry. LGND is outperformed by 60.94% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 9.12
Altman-Z 5.82
ROIC/WACC0.27
WACC9%
LGND Yearly LT Debt VS Equity VS FCFLGND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 22.23 indicates that LGND has no problem at all paying its short term obligations.
  • LGND's Current ratio of 22.23 is amongst the best of the industry. LGND outperforms 92.71% of its industry peers.
  • LGND has a Quick Ratio of 21.98. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 21.98, LGND belongs to the best of the industry, outperforming 92.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 22.23
Quick Ratio 21.98
LGND Yearly Current Assets VS Current LiabilitesLGND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. LGND Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 40.81% over the past year.
  • Measured over the past years, LGND shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.06% on average per year.
  • LGND shows a strong growth in Revenue. In the last year, the Revenue has grown by 60.40%.
  • LGND shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.54% yearly.
EPS 1Y (TTM)40.81%
EPS 3Y23.39%
EPS 5Y12.06%
EPS Q2Q%59.06%
Revenue 1Y (TTM)60.4%
Revenue growth 3Y10.97%
Revenue growth 5Y7.54%
Sales Q2Q%39.37%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.98% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 13.58% on average over the next years. This is quite good.
EPS Next Y5.61%
EPS Next 2Y10.48%
EPS Next 3Y9.34%
EPS Next 5Y12.98%
Revenue Next Year10.34%
Revenue Next 2Y14.55%
Revenue Next 3Y13.78%
Revenue Next 5Y13.58%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LGND Yearly Revenue VS EstimatesLGND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
LGND Yearly EPS VS EstimatesLGND Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

4

4. LGND Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 25.32, which means the current valuation is very expensive for LGND.
  • Compared to the rest of the industry, the Price/Earnings ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 79.69% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.17. LGND is around the same levels.
  • The Price/Forward Earnings ratio is 23.98, which indicates a rather expensive current valuation of LGND.
  • Based on the Price/Forward Earnings ratio, LGND is valued a bit cheaper than the industry average as 75.52% of the companies are valued more expensively.
  • LGND is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.05, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 25.32
Fwd PE 23.98
LGND Price Earnings VS Forward Price EarningsLGND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, LGND is valued a bit cheaper than 76.04% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, LGND is valued a bit cheaper than the industry average as 75.52% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 83.01
EV/EBITDA 38.7
LGND Per share dataLGND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates LGND does not grow enough to justify the current Price/Earnings ratio.
  • LGND has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)4.51
PEG (5Y)2.1
EPS Next 2Y10.48%
EPS Next 3Y9.34%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LGND Dividend Analysis

5.1 Amount

  • No dividends for LGND!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LGND Fundamentals: All Metrics, Ratios and Statistics

LIGAND PHARMACEUTICALS

NASDAQ:LGND (4/6/2026, 4:10:09 PM)

After market: 203.61 0 (0%)

203.61

+4.02 (+2.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners106.63%
Inst Owner Change0%
Ins Owners1.81%
Ins Owner Change2.62%
Market Cap4.06B
Revenue(TTM)268.09M
Net Income(TTM)124.45M
Analysts86.67
Price Target250 (22.78%)
Short Float %7.49%
Short Ratio6.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)42.08%
Min EPS beat(2)26.84%
Max EPS beat(2)57.31%
EPS beat(4)4
Avg EPS beat(4)25.53%
Min EPS beat(4)7.61%
Max EPS beat(4)57.31%
EPS beat(8)8
Avg EPS beat(8)27.71%
EPS beat(12)12
Avg EPS beat(12)54.84%
EPS beat(16)15
Avg EPS beat(16)61.79%
Revenue beat(2)2
Avg Revenue beat(2)25.06%
Min Revenue beat(2)5.23%
Max Revenue beat(2)44.89%
Revenue beat(4)4
Avg Revenue beat(4)17.85%
Min Revenue beat(4)5.23%
Max Revenue beat(4)44.89%
Revenue beat(8)8
Avg Revenue beat(8)17.07%
Revenue beat(12)12
Avg Revenue beat(12)15.78%
Revenue beat(16)14
Avg Revenue beat(16)16.03%
PT rev (1m)0.68%
PT rev (3m)0.68%
EPS NQ rev (1m)7.61%
EPS NQ rev (3m)5.45%
EPS NY rev (1m)0%
EPS NY rev (3m)0.91%
Revenue NQ rev (1m)-1.26%
Revenue NQ rev (3m)-1.72%
Revenue NY rev (1m)0.87%
Revenue NY rev (3m)0.52%
Valuation
Industry RankSector Rank
PE 25.32
Fwd PE 23.98
P/S 15.14
P/FCF 83.01
P/OCF 82.25
P/B 3.99
P/tB 8.23
EV/EBITDA 38.7
EPS(TTM)8.04
EY3.95%
EPS(NY)8.49
Fwd EY4.17%
FCF(TTM)2.45
FCFY1.2%
OCF(TTM)2.48
OCFY1.22%
SpS13.44
BVpS51.01
TBVpS24.74
PEG (NY)4.51
PEG (5Y)2.1
Graham Number96.06
Profitability
Industry RankSector Rank
ROA 7.97%
ROE 12.23%
ROCE 3.1%
ROIC 2.45%
ROICexc 4.72%
ROICexgc 14.03%
OM 17.61%
PM (TTM) 46.42%
GM 94.57%
FCFM 18.24%
ROA(3y)4.72%
ROA(5y)2.84%
ROE(3y)6.4%
ROE(5y)4.11%
ROIC(3y)1.82%
ROIC(5y)2.16%
ROICexc(3y)3.31%
ROICexc(5y)3.45%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.31%
ROCE(5y)2.73%
ROICexgc growth 3YN/A
ROICexgc growth 5Y2.34%
ROICexc growth 3Y108.05%
ROICexc growth 5Y42.36%
OM growth 3Y125.81%
OM growth 5Y30.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.97%
GM growth 5Y2.47%
F-Score5
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 9.12
Debt/EBITDA 5.51
Cap/Depr 1.34%
Cap/Sales 0.17%
Interest Coverage 147.04
Cash Conversion 60.96%
Profit Quality 39.3%
Current Ratio 22.23
Quick Ratio 21.98
Altman-Z 5.82
F-Score5
WACC9%
ROIC/WACC0.27
Cap/Depr(3y)60.81%
Cap/Depr(5y)46.88%
Cap/Sales(3y)16.73%
Cap/Sales(5y)12.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.81%
EPS 3Y23.39%
EPS 5Y12.06%
EPS Q2Q%59.06%
EPS Next Y5.61%
EPS Next 2Y10.48%
EPS Next 3Y9.34%
EPS Next 5Y12.98%
Revenue 1Y (TTM)60.4%
Revenue growth 3Y10.97%
Revenue growth 5Y7.54%
Sales Q2Q%39.37%
Revenue Next Year10.34%
Revenue Next 2Y14.55%
Revenue Next 3Y13.78%
Revenue Next 5Y13.58%
EBIT growth 1Y108.55%
EBIT growth 3Y150.57%
EBIT growth 5Y40.24%
EBIT Next Year256.46%
EBIT Next 3Y62.3%
EBIT Next 5Y45.87%
FCF growth 1Y-48.64%
FCF growth 3Y-25.86%
FCF growth 5Y-0.48%
OCF growth 1Y-49.14%
OCF growth 3Y-29%
OCF growth 5Y-2%

LIGAND PHARMACEUTICALS / LGND Fundamental Analysis FAQ

What is the ChartMill fundamental rating of LIGAND PHARMACEUTICALS (LGND) stock?

ChartMill assigns a fundamental rating of 6 / 10 to LGND.


What is the valuation status for LGND stock?

ChartMill assigns a valuation rating of 4 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.


Can you provide the profitability details for LIGAND PHARMACEUTICALS?

LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 8 / 10.


Can you provide the financial health for LGND stock?

The financial health rating of LIGAND PHARMACEUTICALS (LGND) is 6 / 10.


What is the earnings growth outlook for LIGAND PHARMACEUTICALS?

The Earnings per Share (EPS) of LIGAND PHARMACEUTICALS (LGND) is expected to grow by 5.61% in the next year.